An oral JAK1/TYK2 inhibitor in atopic dermatitis: strong phase 2 signal

Design

Phase 2, randomised, double-blind, placebo-controlled, dose-finding

Population

200 adults with moderate-to-severe atopic dermatitis

Primary outcome

EASI-75 at week 12

Effect

72.9%, 84.7%, 81.4% (5, 10, 20 mg BID) vs 18.5% placebo; all p < 0.0001

A double-blind, placebo-controlled phase 2 trial in a single country randomised 200 adults with moderate-to-severe atopic dermatitis equally to QY201 5 mg, 10 mg or 20 mg twice daily, or placebo, for 12 weeks.

EASI-75 at week 12 was reached by 72.9%, 84.7% and 81.4% on the three doses against 18.5% on placebo (all p < 0.0001). Investigator global assessment response was 44.7%, 64.3% and 71.3% against 12.4%. Adverse events were frequent in all arms — 74.0%, 75.5% and 90.4% against 69.4% — and mostly mild to moderate.

These are large effects, comparable to existing oral JAK inhibitors, but from a short, single-country dose-finding study. The rise in adverse events at 20 mg is worth watching in phase 3, and long-term safety, including the class concerns about thrombosis, infection and malignancy, is unknown.

• QY201 is investigational and not available for prescribing.
• EASI-75 response at 12 weeks was about four times the placebo rate at every dose.
• Adverse events rose to 90.4% at the highest dose, so dose selection in phase 3 matters.
• Existing JAK inhibitors carry boxed warnings; expect the same safety questions for this agent.

Why it matters

Adding TYK2 to JAK1 inhibition is a new route to oral eczema control that may change the JAK safety balance, for better or worse.

Don't overread it

This was a 12-week phase 2 trial in one country; it does not establish safety or long-term benefit.

The statistics, in plain English

Response rates of 73–85% against 18.5% mean roughly two in three treated patients responded who would not have on placebo. A 12-week trial cannot detect rare harms.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.